Investors

Since its founding in 2016, Ikena has raised over $170 million of capital from leading biotechnology investors. This includes a $120 million Series B financing led by Omega Funds, an equity investment as part of the Bristol Myers Squibb collaboration, and a $49 million Series A financing led by OrbiMed and Atlas Venture.

Merck
Merck
Merck
Merck
Merck
Merck
Merck
Merck
Celgene Corporation
Celgene Corporation
Celgene Corporation
Celgene Corporation

Reach out to find out more about how we are discovering and developing cancer therapies.